Adas Darinskas

1.5k total citations · 1 hit paper
22 papers, 1.2k citations indexed

About

Adas Darinskas is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Adas Darinskas has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Immunology. Recurrent topics in Adas Darinskas's work include Immunotherapy and Immune Responses (6 papers), Cancer Research and Treatments (5 papers) and Mesenchymal stem cell research (5 papers). Adas Darinskas is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), Cancer Research and Treatments (5 papers) and Mesenchymal stem cell research (5 papers). Adas Darinskas collaborates with scholars based in Lithuania, Russia and Sweden. Adas Darinskas's co-authors include Marius Strioga, Jaroslav Michálek, Sowmya Viswanathan, Ondřej Slabý, Ludmilla A. Morozova‐Roche, Mantas Mališauskas, Vladimir Zamotin, K. Wilhelm, Sima Rekštytė and Romaldas Mačiulaitis and has published in prestigious journals such as Journal of Biological Chemistry, International Journal of Molecular Sciences and Frontiers in Immunology.

In The Last Decade

Adas Darinskas

20 papers receiving 1.1k citations

Hit Papers

Same or Not the Same? Comparison of Adipose Tissue-Derive... 2012 2026 2016 2021 2012 200 400 600

Peers

Adas Darinskas
Adas Darinskas
Citations per year, relative to Adas Darinskas Adas Darinskas (= 1×) peers Wan Safwani Wan Kamarul Zaman

Countries citing papers authored by Adas Darinskas

Since Specialization
Citations

This map shows the geographic impact of Adas Darinskas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adas Darinskas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adas Darinskas more than expected).

Fields of papers citing papers by Adas Darinskas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adas Darinskas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adas Darinskas. The network helps show where Adas Darinskas may publish in the future.

Co-authorship network of co-authors of Adas Darinskas

This figure shows the co-authorship network connecting the top 25 collaborators of Adas Darinskas. A scholar is included among the top collaborators of Adas Darinskas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adas Darinskas. Adas Darinskas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Селедцов, В. И., Г. В. Селедцова, Adas Darinskas, & Alexei von Delwig. (2025). Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation. International Journal of Molecular Sciences. 26(16). 7724–7724.
2.
Darinskas, Adas, et al.. (2025). Targeting stemness pathways modulates macrophage polarization and reprograms the tumor microenvironment. Frontiers in Immunology. 16. 1513404–1513404. 2 indexed citations
3.
Селедцова, Г. В., et al.. (2025). Tumour-Derived, Extracellular Microvesicles in the Treatment of Acute Renal Failure: An Experimental Study. Medical Sciences. 13(2). 35–35.
4.
Vadalà, Gianluca, Luca Ambrosio, Giuseppina Di Giacomo, et al.. (2023). Wharton's Jelly mesenchymal stromal cell‐derived extracellular vesicles promote nucleus pulposus cell anabolism in an in vitro 3D alginate‐bead culture model. JOR Spine. 7(1). e1274–e1274. 12 indexed citations
5.
Селедцов, В. И., Adas Darinskas, Alexei von Delwig, & Г. В. Селедцова. (2023). Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment. Metabolites. 13(1). 123–123. 3 indexed citations
6.
Skapas, Martynas, et al.. (2021). Comparative Evaluation of Cellular Uptake of Free and Liposomal Doxorubicin Following Short Term Exposure. Anticancer Research. 41(5). 2363–2370. 7 indexed citations
7.
Kazlauskas, Arūnas, Adas Darinskas, Rolandas Meškys, Arimantas Tamašauskas, & Jaunius Urbonavičius. (2019). Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy. BMC Cancer. 19(1). 197–197. 10 indexed citations
8.
Pašukonienė, Vita, Adas Darinskas, Živilė Gudlevičienė, et al.. (2018). Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines. Vaccine. 36(29). 4171–4180. 37 indexed citations
9.
Michálek, Jaroslav, et al.. (2018). Stromal vascular fraction cell therapy for osteoarthritis in elderly: Multicenter case-control study. Journal of Clinical Orthopaedics and Trauma. 10(1). 76–80. 22 indexed citations
10.
Darinskas, Adas, Iosif V. Zalutsky, V. A. Kulchitsky, et al.. (2018). Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model. Oncology Letters. 15(4). 5098–5104. 1 indexed citations
11.
Darinskas, Adas, Marius Strioga, Iosif V. Zalutsky, et al.. (2016). Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. Oncology Reports. 37(1). 171–178. 29 indexed citations
12.
Rekštytė, Sima, Adas Darinskas, Aida Laurinavičienė, et al.. (2015). Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography. Biofabrication. 7(1). 15015–15015. 121 indexed citations
13.
Strioga, Marius, et al.. (2014). Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: To use or not to use?. Vaccine. 32(32). 4015–4024. 29 indexed citations
14.
Strioga, Marius, et al.. (2014). Expression of tolerogenic potential-representing markers on clinical-grade therapeutic dendritic cell-based cancer vaccines. Acta medica Lituanica. 20(4). 161–173. 1 indexed citations
15.
Strioga, Marius, Sowmya Viswanathan, Adas Darinskas, Ondřej Slabý, & Jaroslav Michálek. (2012). Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells. Stem Cells and Development. 21(14). 2724–2752. 663 indexed citations breakdown →
16.
Wilhelm, K., Adas Darinskas, Wim Noppe, et al.. (2009). Protein oligomerization induced by oleic acid at the solid–liquid interface – equine lysozyme cytotoxic complexes. FEBS Journal. 276(15). 3975–3989. 55 indexed citations
17.
Wilhelm, K., Kiran Yanamandra, M. A. Gruden, et al.. (2007). Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. European Journal of Neurology. 14(3). 327–334. 72 indexed citations
18.
Darinskas, Adas, et al.. (2007). Engrafting fetal liver cells into multiple tissues of healthy adult mice without the use of immunosuppressants. Cellular & Molecular Biology Letters. 12(3). 422–34. 3 indexed citations
19.
Mališauskas, Mantas, Adas Darinskas, Vladimir Zamotin, et al.. (2006). Intermediate amyloid oligomers of lysozyme: Is their cytotoxicity a particular case or general rule for amyloid?. Biochemistry (Moscow). 71(5). 505–512. 18 indexed citations
20.
Mališauskas, Mantas, Johan Östman, Adas Darinskas, et al.. (2004). Does the Cytotoxic Effect of Transient Amyloid Oligomers from Common Equine Lysozyme in Vitro Imply Innate Amyloid Toxicity?. Journal of Biological Chemistry. 280(8). 6269–6275. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026